Australian biotech company, Alterity Therapeutics Limited, is aiming to combat several neurological disorders - including Alzheimer's, Huntington's, and Parkinson's diseases - by developing therapeutic drugs. The company's lead drug candidate, ATH434, has concluded Phase I clinical trials in the treatment of Parkinson's disease. Additionally, Alterity Therapeutics Limited is working on PBT2, a drug that has completed Phase 2a clinical trials to treat Alzheimer's disease. Formerly known as Prana Biotechnology Limited, the Melbourne-based company rebranded in April 2019. Since its incorporation in 1997, it has focused on the research and development of innovative drugs to address debilitating neurological conditions.